Trial Outcomes & Findings for Influence of Edible Marijuana on Endurance Exercise Performance (NCT NCT05192239)

NCT ID: NCT05192239

Last Updated: 2024-04-22

Results Overview

Separated by a minimum of a 4 day washout period between randomized crossover coded interventions. Blood will be collected to determine Blood Lactate Levels during standard exercise following ingestion of placebo or active formula.

Recruitment status

COMPLETED

Study phase

EARLY_PHASE1

Target enrollment

17 participants

Primary outcome timeframe

Blood was collected at timepoints 0 minutes (0 watts), 8 minutes (50 watts), 16 minutes (100 watts), and 24 minutes (150 watts) for analysis of blood lactate.

Results posted on

2024-04-22

Participant Flow

Seventeen adults were assessed for eligibility and enrolled in the study. Two adults declined invitations to schedule post-screening study visits, two were excluded from participation on account of use of contraindicated medications, and three were discontinued during the habituation visits as they were unable to sustain the required work rate. This all occurred prior to treatment assignments (randomization).

Participant milestones

Participant milestones
Measure
THC Gummy First, Then Placebo Gummy
Delta-9-tetrahydrocannabinol (THC) 5 milligrams (mg) in gummy form. One time, two gummies will be ingested prior to an exercise bout. THC 5: 5 milligrams of THC in gummy form 4-day minimum washout period Delta-9-tetrahydrocannabinol (THC) free fruit snack gummy. One time, two gummies will be ingested prior to an exercise bout. Placebo: Commercially available non-THC fruit snack
Placebo Gummy First, Then THC Gummy
Delta-9-tetrahydrocannabinol (THC) free fruit snack gummy. One time, two gummies will be ingested prior to an exercise bout. Placebo: Commercially available non-THC fruit snack 4-day minimum washout period Delta-9-tetrahydrocannabinol (THC) 5 milligrams (mg) in gummy form. One time, two gummies will be ingested prior to an exercise bout. THC 5: 5 milligrams of THC in gummy form
Overall Study
STARTED
5
5
Overall Study
COMPLETED
5
5
Overall Study
NOT COMPLETED
0
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Race and Ethnicity were not collected from any participant.

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Randomized Crossover Study
n=9 Participants
Participants first received either a Placebo gummy (commercially available non-THC fruit snack) or 2 5mg THC gummies prior to an exercise bout. Visits were separated by a 4-day washout period.
Age, Continuous
25 years
STANDARD_DEVIATION 3 • n=9 Participants
Sex: Female, Male
Female
1 Participants
n=9 Participants
Sex: Female, Male
Male
8 Participants
n=9 Participants
Height
167.3 cm
STANDARD_DEVIATION 25.5 • n=9 Participants
Body Mass
75.97 kg
STANDARD_DEVIATION 13.30 • n=9 Participants
Lean Mass
57.98 kg
STANDARD_DEVIATION 9.79 • n=9 Participants
Body Fat
20.12 % of body fat
STANDARD_DEVIATION 3.05 • n=9 Participants
VO2 peak
56.5 ml/kg/min
STANDARD_DEVIATION 11.7 • n=9 Participants

PRIMARY outcome

Timeframe: Blood was collected at timepoints 0 minutes (0 watts), 8 minutes (50 watts), 16 minutes (100 watts), and 24 minutes (150 watts) for analysis of blood lactate.

Separated by a minimum of a 4 day washout period between randomized crossover coded interventions. Blood will be collected to determine Blood Lactate Levels during standard exercise following ingestion of placebo or active formula.

Outcome measures

Outcome measures
Measure
Placebo
n=9 Participants
Delta-9-tetrahydrocannabinol (THC) free fruit snack gummy. One time, two gummies will be ingested prior to an exercise bout. Placebo: Commercially available non-THC fruit snack
10 mg THC
n=9 Participants
Delta-9-tetrahydrocannabinol (THC) 5 milligrams (mg) in gummy form. One time, two gummies will be ingested prior to an exercise bout. THC 5: 5 milligrams of THC in gummy form
Comparison of Blood Lactate Levels During a 24 Minute Graded Standard Exercise Test (50 Watts, 100 Watts, and 150 Watts) to Placebo.
0 minutes - 0 watts
0.9699 mmol/L
Standard Deviation 0.3711208
1.1437 mmol/L
Standard Deviation 0.358376
Comparison of Blood Lactate Levels During a 24 Minute Graded Standard Exercise Test (50 Watts, 100 Watts, and 150 Watts) to Placebo.
8 minutes - 50 watts
1.26345 mmol/L
Standard Deviation 0.47071
1.3618 mmol/L
Standard Deviation 0.343596
Comparison of Blood Lactate Levels During a 24 Minute Graded Standard Exercise Test (50 Watts, 100 Watts, and 150 Watts) to Placebo.
16 minutes - 100 watts
1.6075 mmol/L
Standard Deviation 0.9670983
1.3558333 mmol/L
Standard Deviation 0.7374943
Comparison of Blood Lactate Levels During a 24 Minute Graded Standard Exercise Test (50 Watts, 100 Watts, and 150 Watts) to Placebo.
24 minutes - 150 watts
2.5896 mmol/L
Standard Deviation 2.254174
2.4418 mmol/L
Standard Deviation 2.2780711

PRIMARY outcome

Timeframe: Heart rate was measured at timepoints 0 minutes (0 watts), 8 minutes (50 watts), 16 minutes (100 watts) and 24 minutes (150 watts)

Separated by a minimum of a 4 day washout period between randomized crossover coded interventions.Heart rate will be collected during standard graded exercise following ingestion of placebo or active formula (10mg THC in the form of two 5mg gummies).

Outcome measures

Outcome measures
Measure
Placebo
n=9 Participants
Delta-9-tetrahydrocannabinol (THC) free fruit snack gummy. One time, two gummies will be ingested prior to an exercise bout. Placebo: Commercially available non-THC fruit snack
10 mg THC
n=9 Participants
Delta-9-tetrahydrocannabinol (THC) 5 milligrams (mg) in gummy form. One time, two gummies will be ingested prior to an exercise bout. THC 5: 5 milligrams of THC in gummy form
Comparison of Heart Rate During a 24 Minute Graded Standard Exercise Test (50 Watts, 100 Watts, and 150 Watts) to Placebo.
0 minutes - 0 watts
66 bpm
Standard Deviation 16
63 bpm
Standard Deviation 13
Comparison of Heart Rate During a 24 Minute Graded Standard Exercise Test (50 Watts, 100 Watts, and 150 Watts) to Placebo.
8 minutes - 50 watts
95 bpm
Standard Deviation 14
97 bpm
Standard Deviation 15
Comparison of Heart Rate During a 24 Minute Graded Standard Exercise Test (50 Watts, 100 Watts, and 150 Watts) to Placebo.
16 minutes - 100 watts
108 bpm
Standard Deviation 18
113 bpm
Standard Deviation 20
Comparison of Heart Rate During a 24 Minute Graded Standard Exercise Test (50 Watts, 100 Watts, and 150 Watts) to Placebo.
24 minutes - 150 watts
130 bpm
Standard Deviation 26
135 bpm
Standard Deviation 27

PRIMARY outcome

Timeframe: RPE was reported and averaged for each intensity stage at timepoints 0 minutes- 4 minutes (0 watts), 8 minutes-12 minutes (50 watts), 16 minutes-20 minutes (100 watts), and 24 minutes (150 watts).

Separated by a minimum of a 4 day washout period between randomized crossover coded interventions.During standard exercise, participants will be asked to report Rating of Perceived Exertion (RPE) on a scale from 6-20 (6 is no exertion and 20 is maximal exertion) during a graded standard exercise test following ingestion of placebo or active formula.

Outcome measures

Outcome measures
Measure
Placebo
n=9 Participants
Delta-9-tetrahydrocannabinol (THC) free fruit snack gummy. One time, two gummies will be ingested prior to an exercise bout. Placebo: Commercially available non-THC fruit snack
10 mg THC
n=9 Participants
Delta-9-tetrahydrocannabinol (THC) 5 milligrams (mg) in gummy form. One time, two gummies will be ingested prior to an exercise bout. THC 5: 5 milligrams of THC in gummy form
Comparison of Rating of Perceived Exertion (RPE) During a 24 Minute Graded Standard Exercise Test (50 Watts, 100 Watts, and 150 Watts) to Placebo.
0 and 4 minutes - 0 watts
6 units on a scale
Standard Deviation 0
6 units on a scale
Standard Deviation 0
Comparison of Rating of Perceived Exertion (RPE) During a 24 Minute Graded Standard Exercise Test (50 Watts, 100 Watts, and 150 Watts) to Placebo.
8 and 12 minutes - 50 watts
8 units on a scale
Standard Deviation 1
8 units on a scale
Standard Deviation 1
Comparison of Rating of Perceived Exertion (RPE) During a 24 Minute Graded Standard Exercise Test (50 Watts, 100 Watts, and 150 Watts) to Placebo.
16 and 20 minutes - 100 watts
11 units on a scale
Standard Deviation 1
10 units on a scale
Standard Deviation 1
Comparison of Rating of Perceived Exertion (RPE) During a 24 Minute Graded Standard Exercise Test (50 Watts, 100 Watts, and 150 Watts) to Placebo.
24 minutes - 150 watts
12 units on a scale
Standard Deviation 1
12 units on a scale
Standard Deviation 1

PRIMARY outcome

Timeframe: Expired gasses were measured and averaged during three time points, 5-8 minutes (50 Watts), 13-16 minutes (150 Watts), and 21-24 minutes (150 Watts).

Separated by a minimum of a 4 day washout period between randomized crossover coded interventionsVO2 will be collected during graded standard exercise following ingestion of placebo or active formula. Expired gasses were measured and averaged during three time points, 5-8 minutes, 13-16 minutes, and 21-24 minutes. Gasses were not collected or recorded outside of those timeframes.

Outcome measures

Outcome measures
Measure
Placebo
n=9 Participants
Delta-9-tetrahydrocannabinol (THC) free fruit snack gummy. One time, two gummies will be ingested prior to an exercise bout. Placebo: Commercially available non-THC fruit snack
10 mg THC
n=9 Participants
Delta-9-tetrahydrocannabinol (THC) 5 milligrams (mg) in gummy form. One time, two gummies will be ingested prior to an exercise bout. THC 5: 5 milligrams of THC in gummy form
Comparison of Indirect Calorimetry (VO2) During a 24 Minute Graded Standard Exercise Test (50 Watts, 100 Watts, and 150 Watts) to Placebo.
5-8 minutes- 50 watts
1.26404 L/min
Standard Deviation 0.31999
1.24939816 L/min
Standard Deviation 0.15584784
Comparison of Indirect Calorimetry (VO2) During a 24 Minute Graded Standard Exercise Test (50 Watts, 100 Watts, and 150 Watts) to Placebo.
13-16 minutes-100 watts
1.66361 L/min
Standard Deviation 0.18041
1.664867728 L/min
Standard Deviation 0.138618921
Comparison of Indirect Calorimetry (VO2) During a 24 Minute Graded Standard Exercise Test (50 Watts, 100 Watts, and 150 Watts) to Placebo.
21-24 minutes- 150 watts
2.11388 L/min
Standard Deviation 0.15106
2.126941406 L/min
Standard Deviation 0.133666814

PRIMARY outcome

Timeframe: Separated by a minimum of a 4 day washout period between randomized crossover coded interventions

Mean maximal power will be measured over 20 minutes following ingestion of placebo or active formula

Outcome measures

Outcome measures
Measure
Placebo
n=9 Participants
Delta-9-tetrahydrocannabinol (THC) free fruit snack gummy. One time, two gummies will be ingested prior to an exercise bout. Placebo: Commercially available non-THC fruit snack
10 mg THC
n=9 Participants
Delta-9-tetrahydrocannabinol (THC) 5 milligrams (mg) in gummy form. One time, two gummies will be ingested prior to an exercise bout. THC 5: 5 milligrams of THC in gummy form
Comparison of Maximal Mean Power Output to Placebo
422 watts
Standard Deviation 92
454 watts
Standard Deviation 77

PRIMARY outcome

Timeframe: Separated by a minimum of a 4 day washout period between randomized crossover coded interventions.

Cycling until Time to Exhaustion in seconds following ingestion of placebo or active formula during high intensity exercise

Outcome measures

Outcome measures
Measure
Placebo
n=9 Participants
Delta-9-tetrahydrocannabinol (THC) free fruit snack gummy. One time, two gummies will be ingested prior to an exercise bout. Placebo: Commercially available non-THC fruit snack
10 mg THC
n=9 Participants
Delta-9-tetrahydrocannabinol (THC) 5 milligrams (mg) in gummy form. One time, two gummies will be ingested prior to an exercise bout. THC 5: 5 milligrams of THC in gummy form
Comparison of Time to Exhaustion to Placebo
43 seconds
Standard Deviation 33
43 seconds
Standard Deviation 32

Adverse Events

Placebo

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

10 mg THC

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Christopher Bell, Associate Professor

Colorado State University

Phone: (970) 491-7522

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place